The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling Review
Abstract
CONTEXT: Selective eligibility criteria of randomized controlled trials (RCTs) are vital to trial feasibility and internal validity. However, the exclusion of certain patient populations may lead to impaired generalizability of results. OBJECTIVE: To determine the nature and extent of exclusion criteria among RCTs published in major medical journals and the contribution of exclusion criteria to the representation of certain patient populations. DATA SOURCES AND STUDY SELECTION: The MEDLINE database was searched for RCTs published between 1994 and 2006 in certain general medical journals with a high impact factor. Of 4827 articles, 283 were selected using a series technique. DATA EXTRACTION: Trial characteristics and the details regarding exclusions were extracted independently. All exclusion criteria were graded independently and in duplicate as either strongly justified, potentially justified, or poorly justified according to previously developed and pilot-tested guidelines. DATA SYNTHESIS: Common medical conditions formed the basis for exclusion in 81.3% of trials. Patients were excluded due to age in 72.1% of all trials (60.1% in pediatric populations and 38.5% in older adults). Individuals receiving commonly prescribed medications were excluded in 54.1% of trials. Conditions related to female sex were grounds for exclusion in 39.2% of trials. Of all exclusion criteria, only 47.2% were graded as strongly justified in the context of the specific RCT. Exclusion criteria were not reported in 12.0% of trials. Multivariable analyses revealed independent associations between the total number of exclusion criteria and drug intervention trials (risk ratio, 1.35; 95% confidence interval, 1.11-1.65; P = .003) and between the total number of exclusion criteria and multicenter trials (risk ratio, 1.26; 95% confidence interval, 1.06-1.52; P = .009). Industry-sponsored trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, and age. Drug intervention trials were more likely to exclude individuals due to concomitant medication use, medical comorbidities, female sex, and socioeconomic status. Among such trials, justification for exclusions related to concomitant medication use and comorbidities were more likely to be poorly justified. CONCLUSIONS: The RCTs published in major medical journals do not always clearly report exclusion criteria. Women, children, the elderly, and those with common medical conditions are frequently excluded from RCTs. Trials with multiple centers and those involving drug interventions are most likely to have extensive exclusions. Such exclusions may impair the generalizability of RCT results. These findings highlight a need for careful consideration and transparent reporting and justification of exclusion criteria in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723
Cited by
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
CONSORT 2010 statement: extension to randomised pilot and feasibility trials.
Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · BMJ · doi:10.1136/bmj.i5239 · Cited by 3,404
“71 Additionally, for pilot trials it is important to know how many participants were approached before being evaluated for potential enrolment in the trial and how easy it was to recruit them, in order to assess the potential for enrolment for the future definitive RCT and other future trials.”
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
on behalf of the PAFS consensus group, Eldridge, S. M., Chan, C. L., Campbell, M. J., Bond, C. M., Hopewell, S., Thabane, L., & Lancaster, G. A. (2016) · Pilot and Feasibility Studies · doi:10.1186/s40814-016-0105-8 · Cited by 2,843
Improving the reporting of pragmatic trials: An extension of the CONSORT statement
Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., Moher, D., & groups, F. T. C. A. P. T. I. H. (. (2008) · BMJ · doi:10.1136/bmj.a2390 · Cited by 1,813
Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., & Johnston, J. (2015) · Trials · doi:10.1186/s13063-015-1023-4 · Cited by 878
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Adverse drug reactions in special populations – the elderly
Davies, E. A., & O'Mahony, M. S. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12596 · Cited by 604
Adapting clinical guidelines to take account of multimorbidity
Guthrie, B., Payne, K., Alderson, P., McMurdo, M. E. T., & Mercer, S. W. (2012) · BMJ · doi:10.1136/bmj.e6341 · Cited by 530
Hughes, L. D., McMurdo, M. E. T., & Guthrie, B. (2013) · Age and Ageing · doi:10.1093/ageing/afs100 · Cited by 506
Aubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344
Mining Electronic Health Records (EHRs): A Survey
Yadav, P., Steinbach, M., Kumar, V., & Simon, G. (2018) · ACM Computing Surveys · doi:10.1145/3127881 · Cited by 299
Zabor, E. C., Kaizer, A. M., & Hobbs, B. P. (2020) · Chest · doi:10.1016/j.chest.2020.03.013 · Cited by 294
Randomized controlled trials – a matter of design
Siepmann, T., Spieth, P. M., Kubasch, A. S., Penzlin, A. I., Illigens, B. M.-W., & Barlinn, K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s101938 · Cited by 292
ESMO guidance for reporting oncology real-world evidence (GROW)
Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.001 · Cited by 247
Kass, N. E., Faden, R. R., Goodman, S. N., Pronovost, P., Tunis, S., & Beauchamp, T. L. (2013) · Hastings Center Report · doi:10.1002/hast.133 · Cited by 235
CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081124 · Cited by 205
Uhlig, K., Leff, B., Kent, D., Dy, S., Brunnhuber, K., Burgers, J. S., Greenfield, S., Guyatt, G., High, K., Leipzig, R., et al. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2659-y · Cited by 158
He, J., Morales, D. R., & Guthrie, B. (2020) · Trials · doi:10.1186/s13063-020-4139-0 · Cited by 147
SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials
Hróbjartsson, A., Boutron, I., Hopewell, S., Moher, D., Schulz, K. F., Collins, G. S., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081660 · Cited by 171
Averitt, A. J., Weng, C., Ryan, P., & Perotte, A. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0277-8 · Cited by 137
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Duff, J. M., Leather, H., Walden, E. O., LaPlant, K. D., & George, T. J. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq117 · Cited by 103
Treatment as usual and routine care in research and clinical practice
Kazdin, A. E. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.08.006 · Cited by 96
Reporting of participant flow diagrams in published reports of randomized trials
Hopewell, S., Hirst, A., Collins, G. S., Mallett, S., Yu, L.-M., & Altman, D. G. (2011) · Trials · doi:10.1186/1745-6215-12-253 · Cited by 84
Older patients are still under-represented in clinical trials of Alzheimer's disease
Banzi, R., Camaioni, P., Tettamanti, M., Bertele’, V., & Lucca, U. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0201-2 · Cited by 74
Getawen, S. K., Ashine, T., Massebo, F., Woldeyes, D., & Lindtjørn, B. (2018) · Acta Tropica · doi:10.1016/j.actatropica.2018.02.009 · Cited by 68
Glasgow, R. E., Strycker, L. A., Kurz, D., Faber, A., Bell, H., Dickman, J. M., Halterman, E., Estabrooks, P. A., & Osuna, D. (2010) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9189-1 · Cited by 60
Multimorbidity: Implications and directions for health psychology and behavioral medicine.
Suls, J., Green, P. A., & Boyd, C. M. (2019) · Health Psychology · doi:10.1037/hea0000762 · Cited by 52
Ladebo, L., Ernst, M. T., Mailhac, A., Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024) · Diabetes Care · doi:10.2337/dc24-1082 · Cited by 46
Blumle, A., Meerpohl, J. J., Rucker, G., Antes, G., Schumacher, M., & von Elm, E. (2011) · BMJ · doi:10.1136/bmj.d1828 · Cited by 44
Chong, K., & Unruh, M. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw399 · Cited by 42
Schuetz, P. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14132 · Cited by 42
Potential for epistemic injustice in evidence-based healthcare policy and guidance
Michaels, J. A. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106171 · Cited by 41
de Boer, R. A., Doehner, W., van der Horst, I. C. C., Anker, S. D., Babalis, D., Roughton, M., Coats, A. J., Flather, M. D., & van Veldhuisen, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.02.018 · Cited by 39
Benefit and harms of new anti-cancer drugs
Vera-Badillo, F. E., Al-Mubarak, M., Templeton, A. J., & Amir, E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0303-y · Cited by 35
Pressler, T. R., & Kaizar, E. E. (2013) · Statistics in Medicine · doi:10.1002/sim.5802 · Cited by 32
Guideline recommended treatments in complex patients with multimorbidity
Muth, C., & Glasziou, P. P. (2015) · BMJ · doi:10.1136/bmj.h5145 · Cited by 28
Charlson, M. E., & Wells, M. T. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000521952 · Cited by 25
Patient attrition in Molecular Tumour Boards: a systematic review
Frost, H., Graham, D. M., Carter, L., O’Regan, P., Landers, D., & Freitas, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01922-3 · Cited by 17
Gressies, C., Kaegi-Braun, N., Gomes, F., & Schuetz, P. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2022.11.007 · Cited by 5
Metadata
- Authors
- Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-03-21
- Volume
- 297
- Issue
- 11
- Pages
- 1233
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2043990618
- Cited by
- 1,055
- References
- 5
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.